Document Detail


Cost-benefit and cost-effectiveness of the incorporation of the pneumococcal 7-valent conjugated vaccine in the routine vaccination schedule of Catalonia (Spain).
MedLine Citation:
PMID:  15755625     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The health and economic costs and benefits of vaccinating a cohort of 60,000 children born in Catalonia in the year 2000 with the pneumococcal 7-valent conjugated vaccine were compared with the alternative of not implementing the vaccination programme. The time horizon fixed for the programme was 10 years for invasive disease, 2 years for all episodes of pneumonia and otitis media and 3.5 years for the placement of tympanostomy tubes. In the base case (incidence rate of invasive disease of 160 per 100,000 and price of the vaccine 50 euros) the net present value was negative, both from the societal perspective (-5.1million euros) and from the provider's perspective (-9.2million euros). The benefit-cost ratio was 0.59 euros from the societal perspective. The cost per disability adjusted life year (DALY) gained was 44,307 euros from the societal perspective and 80,291 euros from the provider's perspective.
Authors:
E Navas; L Salleras; R Gisbert; A Domínguez; E Timoner; D Ibáñez; A Prat
Related Documents :
18848595 - Rabies control in rural africa: evaluating strategies for effective domestic dog vaccin...
21075265 - Residual economic burden of streptococcus pneumoniae- and nontypeable haemophilus influ...
25236585 - Parental preferences for rotavirus vaccination in young children: a discrete choice exp...
18282015 - Cost-effectiveness analyses of vaccination programmes : a focused review of modelling a...
21593255 - Genotype diversity and distribution of orientia tsutsugamushi causing scrub typhus in t...
18766555 - Comparison of intramuscular and subcutaneous administration of marek's disease vaccine.
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Vaccine     Volume:  23     ISSN:  0264-410X     ISO Abbreviation:  Vaccine     Publication Date:  2005 Mar 
Date Detail:
Created Date:  2005-03-09     Completed Date:  2005-05-18     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8406899     Medline TA:  Vaccine     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  2342-8     Citation Subset:  IM    
Affiliation:
General-Directorate of Public Health, Department of Health, Generalitat of Catalonia, Travessera de les Corts, 131-159, 08028 Barcelona, Spain. e.navas@gencat.net
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Child, Preschool
Cohort Studies
Cost-Benefit Analysis
Humans
Immunization Schedule
Infant
Otitis Media / economics,  epidemiology,  prevention & control
Pneumococcal Infections / economics,  epidemiology,  mortality,  prevention & control
Pneumococcal Vaccines / administration & dosage*,  economics*
Pneumonia, Pneumococcal / economics,  epidemiology,  mortality,  prevention & control
Spain / epidemiology
Vaccines, Conjugate / administration & dosage,  economics
Chemical
Reg. No./Substance:
0/Pneumococcal Vaccines; 0/Vaccines, Conjugate

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Fusing subunit antigens to interleukin-2 and encapsulating them in liposomes improves their antigeni...
Next Document:  Surveillance system of vaccine adverse events and local data analysis--the experience in a middle-si...